Literature DB >> 33526068

Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression.

Shijun Yu1, Li Li1, Hui Cai2, Bin He1, Yong Gao3, Yandong Li4.   

Abstract

BACKGROUND: Accumulating evidence has highlighted the importance of negative elongation factor complex member E (NELFE) in tumorigenesis. However, the relationship between NELFE and gastric cancer (GC) remains unclear. This study aimed to explore the expression pattern and specific function of NELFE in GC.
METHODS: NELFE expression was evaluated by immunohistochemistry and qRT-PCR in GC tissues, respectively. Cell proliferation, migration and invasion were measured by CCK-8, colony formation, transwell assays, and nude mice model. Bioinformatics analysis was performed to search potential target genes of NELFE, and a Cignal Finder 10-Pathway Reporter Array was used to explore potential signaling pathways regulated by NELFE. Dual-luciferase reporter assays, qRT-PCR and western blotting were conducted to verify their regulatory relationship. The expression correlations among NELFE, β-catenin and CSNK2B were further explored by immunohistochemistry on consecutive resections.
RESULTS: NELFE was significantly overexpressed in GC tissues both in protein and mRNA level and negatively correlated with the prognosis of GC patients. Gain- and loss-of-function experiments showed that NELFE potentiated GC cell proliferation and metastasis in vitro and in vivo. CSNK2B was identified as a downstream effector of NELFE. Wnt/β-catenin signaling may mediate the regulation of CSNK2B by NELFE. In addition, NELFE, β-catenin and CSNK2B were all remarkably upregulated in tumor tissues compared with adjacent normal tissues, and their expression levels in GC were positively correlated with each other.
CONCLUSION: Our findings reveal a new NELFE-Wnt/β-catenin-CSNK2B axis to promote GC progression and provide new candidate targets against this disease.

Entities:  

Keywords:  CSNK2B; Gastric cancer; NELFE; Tumorigenesis; Wnt/β-catenin

Year:  2021        PMID: 33526068      PMCID: PMC7851912          DOI: 10.1186/s13046-021-01848-3

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  32 in total

1.  A small-molecule agonist of the Wnt signaling pathway.

Authors:  Jun Liu; Xu Wu; Brian Mitchell; Chris Kintner; Sheng Ding; Peter G Schultz
Journal:  Angew Chem Int Ed Engl       Date:  2005-03-18       Impact factor: 15.336

Review 2.  Basic mechanisms of transcript elongation and its regulation.

Authors:  S M Uptain; C M Kane; M J Chamberlin
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

3.  Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.

Authors:  Hien Dang; Atsushi Takai; Marshonna Forgues; Yotsowat Pomyen; Haiwei Mou; Wen Xue; Debashish Ray; Kevin C H Ha; Quaid D Morris; Timothy R Hughes; Xin Wei Wang
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

4.  Overexpression of the RD RNA binding protein in hepatitis C virus-related hepatocellular carcinoma.

Authors:  Michihisa Iida; Norio Iizuka; Ryouichi Tsunedomi; Masahiro Tsutsui; Shin Yoshida; Yoshinari Maeda; Yoshihiro Tokuhisa; Kazuhiko Sakamoto; Kiyoshi Yoshimura; Takao Tamesa; Masaaki Oka
Journal:  Oncol Rep       Date:  2012-05-18       Impact factor: 3.906

5.  Structure and function of the human transcription elongation factor DSIF.

Authors:  Y Yamaguchi; T Wada; D Watanabe; T Takagi; J Hasegawa; H Handa
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

6.  Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex.

Authors:  Takashi Narita; Yuki Yamaguchi; Keiichi Yano; Seiji Sugimoto; Sittinan Chanarat; Tadashi Wada; Dong-ki Kim; Jun Hasegawa; Masashi Omori; Naoto Inukai; Masaki Endoh; Tomoko Yamada; Hiroshi Handa
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

7.  The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.

Authors:  Yue Song; Zhao-Xia Li; Xi Liu; Rui Wang; Li-Wei Li; Qingyu Zhang
Journal:  Tumour Biol       Date:  2017-07

8.  Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients.

Authors:  A Marcell Szász; András Lánczky; Ádám Nagy; Susann Förster; Kim Hark; Jeffrey E Green; Alex Boussioutas; Rita Busuttil; András Szabó; Balázs Győrffy
Journal:  Oncotarget       Date:  2016-08-02

9.  Huaier Suppresses Breast Cancer Progression via linc00339/miR-4656/CSNK2B Signaling Pathway.

Authors:  Wei Wang; Xiaolong Wang; Chen Li; Tong Chen; Ning Zhang; Yiran Liang; Yaming Li; Hanwen Zhang; Ying Liu; Xiaojin Song; Wenjing Zhao; Bing Chen; Lijuan Wang; Qifeng Yang
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

10.  Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.

Authors:  Ye Xiao; Shulan Huang; Feng Qiu; Xiaofeng Ding; Yi Sun; Chenxi Wei; Xiang Hu; Ke Wei; Shengwen Long; Lina Xie; Yu Xun; Wen Chen; Zhijian Zhang; Ning Liu; Shuanglin Xiang
Journal:  EBioMedicine       Date:  2020-01-03       Impact factor: 8.143

View more
  3 in total

Review 1.  The role and therapeutic implication of endoplasmic reticulum stress in inflammatory cancer transformation.

Authors:  Yuan Li; Lu Lu; Guangtao Zhang; Guang Ji; Hanchen Xu
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

2.  AVL9 promotes colorectal carcinoma cell migration via regulating EGFR expression.

Authors:  Qiong Wu; Jing De Chen; Zhuqing Zhou
Journal:  Biol Proced Online       Date:  2022-01-06       Impact factor: 3.244

3.  The RNA-Binding Protein NELFE Promotes Gastric Cancer Growth and Metastasis Through E2F2.

Authors:  Changyu Chen; Qiang Zheng; Shubo Pan; Wenzheng Chen; Jianfeng Huang; Yi Cao; Yi Tu; Zhengrong Li; Changjun Yu; Zhigang Jie
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.